PCA3 and posterior cortical atrophy: The results showed that the expression levels of PCA3 and MALAT1 were both significantly increased in the clinically significant PCa group (GS ≥ 7) compared with the nonaggressive disease group (Figure 2b, PCA3: p < 0.001; MALAT1: p < 0.001).